| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/21/2004 | CA2284034C Comestible capsules having flavoured coatings |
| 09/21/2004 | CA2242986C Sustained release drug formulations |
| 09/21/2004 | CA2241502C A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anti-inflammatory drugs |
| 09/21/2004 | CA2192190C Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material |
| 09/21/2004 | CA2187629C Novel nucleic acid/polymer complexes, method for preparing same and use thereof for cell transfection |
| 09/21/2004 | CA2146757C Stabilization of fluorocarbon emulsions |
| 09/21/2004 | CA2094540C Orally-ingestible nutrition compositions having improved palatability |
| 09/16/2004 | WO2004078933A2 Intracellular delivery of small molecules proteins and nucleic acids |
| 09/16/2004 | WO2004078926A2 Immunologigal markers |
| 09/16/2004 | WO2004078778A2 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF |
| 09/16/2004 | WO2004078216A2 Use of a tricyclic antidepressant drug for promoting endocytosis |
| 09/16/2004 | WO2004078215A2 Use of antibody conjugated deoxycytidine kinase for adept |
| 09/16/2004 | WO2004078214A1 Compositions for nasal absorption |
| 09/16/2004 | WO2004078213A1 Composition for target substance introduction and method of target substance introduction |
| 09/16/2004 | WO2004078212A1 Medicinal composition for regulating release and process for producing the same |
| 09/16/2004 | WO2004078198A1 Long acting injectable insulin composition and methods of making and using thereof |
| 09/16/2004 | WO2004078197A1 Delivery system for drug and cell therapy |
| 09/16/2004 | WO2004078196A1 Oral insulin composition and methods of making and using thereof |
| 09/16/2004 | WO2004078186A1 Ointment preparation for repairing injured skin |
| 09/16/2004 | WO2004078147A2 Oxytocin controlled release formulations and methods of using same |
| 09/16/2004 | WO2004078146A2 Trans-membrane-antibody induced inhibition of apoptosis |
| 09/16/2004 | WO2004078142A2 Compositions and methods for preventing and treating endotoxin-related diseases and conditions |
| 09/16/2004 | WO2004078140A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| 09/16/2004 | WO2004078137A2 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 09/16/2004 | WO2004078122A2 Invisible patch for active agnet controlled delivery |
| 09/16/2004 | WO2004078097A2 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer |
| 09/16/2004 | WO2004078092A2 Cream dispenser |
| 09/16/2004 | WO2004060966A3 Maleamic acid polymer derivatives and their bioconjugates |
| 09/16/2004 | WO2004050679A3 Mutant glycoproteins |
| 09/16/2004 | WO2004050028A3 Density-controlled particulate suspensions for foodstuff, cosmetic, pharmaceutical and other uses |
| 09/16/2004 | WO2004045494A3 Biological glue based on thrombin-conjugated nanoparticles |
| 09/16/2004 | WO2004043389B1 Methods of treating cancer and related methods |
| 09/16/2004 | WO2004026362A3 Dri nasal sprays |
| 09/16/2004 | WO2004025263A3 Protein and peptide expression for passive immunity |
| 09/16/2004 | WO2004022577A3 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 09/16/2004 | WO2004013180A3 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 09/16/2004 | WO2003104432A3 Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| 09/16/2004 | WO2003090682A3 Treatment and prevention of pulmonary conditions |
| 09/16/2004 | WO2003066063A8 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist |
| 09/16/2004 | WO2003066004A3 Therapeutic compounds |
| 09/16/2004 | WO2003053457A8 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 09/16/2004 | WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies |
| 09/16/2004 | WO2003031593A9 MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES |
| 09/16/2004 | WO2003026577A3 P-amidobenzylethers in drug delivery agents |
| 09/16/2004 | WO2002064093A8 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| 09/16/2004 | WO2002050097A3 Anti-allergic complex molecules |
| 09/16/2004 | US20040181114 Methods of enhancing radiation effects with metal nanoparticles |
| 09/16/2004 | US20040181041 Fusion protein capable of inducing programmed cell death for use in treatment cell proliferative diseases and infection |
| 09/16/2004 | US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 09/16/2004 | US20040181034 Multimeric Apo A-I agonist compounds |
| 09/16/2004 | US20040181033 Binding agents which inhibit myostatin |
| 09/16/2004 | US20040180965 Benzydamine hydrochloride, polyoxyalkylene block copolymer, propylene glycol, in water having a pH value in the range of about 3.5 to 7 |
| 09/16/2004 | US20040180962 Dosage forms having prolonged active ingredient release |
| 09/16/2004 | US20040180961 poorly water-soluble aceclofenac, a polymeric base selected from the group consisting of polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, glycerolmonostearate, carbamer and poloxamer, and a surfactant |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180949 conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue |
| 09/16/2004 | US20040180915 Methadone-containing compositions for parenteral administration and method of use thereof |
| 09/16/2004 | US20040180870 Containing propylene glycol and 2-propanol or ethanol; clear, long shelf life; nonirritating, freezing resistance; low cost ear drops |
| 09/16/2004 | US20040180866 Minimizes exposure to hazardous airborne particles; simple, accurate metered dispensing |
| 09/16/2004 | US20040180858 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
| 09/16/2004 | US20040180856 Aqueous solution including partially methylated cyclodextrin |
| 09/16/2004 | US20040180853 Allantoin-containing skin cream |
| 09/16/2004 | US20040180840 Blood brain barrier crossing and/or oral drug delivery; central nervous system tumors and cancer; such as etoposide attached to ethylene glycol oligomer or polymer; blood solubility, in vivo hydrolysis |
| 09/16/2004 | US20040180837 Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier |
| 09/16/2004 | US20040180832 Sustained peptide-release formulation |
| 09/16/2004 | US20040180831 Efficiently lower serum calcium levels, bioavailability; chymotrypsin and/or trypsin degradation resistance; bone disorders |
| 09/16/2004 | US20040180827 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 09/16/2004 | US20040180823 Peptides, peptidomimetics; promoting programmed cell death; neural regeneration |
| 09/16/2004 | US20040180434 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 09/16/2004 | US20040180386 Using major histocompatibility complex polypeptides as tools in identifying lymphocyte binding sites; immunosuppression and tumor therapeutics |
| 09/16/2004 | US20040180097 For encapsulating an unstable drug and/or a drug with unpleasant taste, drug entrapped in pores of grains |
| 09/16/2004 | US20040180091 Carbonated hydroxyapatite-based microspherical composites for biomedical uses |
| 09/16/2004 | US20040180088 Controlled release core is capable of swelling rapidly to at least about two times its original volume, and maintaining its physical integrity in gastrointestinal fluids for prolonged periods |
| 09/16/2004 | US20040180080 Fentanyl compound-containing edible patch to be applied to oral mucosa |
| 09/16/2004 | US20040180077 Unobtrusive, portable edible strip or film that can be administered inconspicuously without the requirement of a liquid to aid in administration |
| 09/16/2004 | US20040180072 Prosthesis with sustained release analgesic |
| 09/16/2004 | US20040180066 Useful for threapy of pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV) |
| 09/16/2004 | US20040180059 For alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject |
| 09/16/2004 | US20040180057 Neutron capture therapy |
| 09/16/2004 | US20040180050 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease |
| 09/16/2004 | US20040180044 For providing insecticidal, fungicidal, deodorizing, mollusicidal, anticorrosive, antistatic, pheromonal, or antiseptic action over an extended period of time |
| 09/16/2004 | US20040180040 Methods and compositions for directing cells to target organs |
| 09/16/2004 | US20040180036 Salts of codrugs and uses related thereto |
| 09/16/2004 | US20040180035 Administering to the mammal (i) an immunoconjugate comprising an antibody binding site capable of binding the preselected cell-type and a cytokine capable of inducing a said immune response against the preselected cell-type, and (ii) an angiogenesis inhibitor to enhance immune response |
| 09/16/2004 | US20040180034 Anthelmintic resinates and a method for their preparation |
| 09/16/2004 | US20040180007 Pharmaceutical chewing gum formulations |
| 09/16/2004 | US20040180001 antitumor |
| 09/16/2004 | US20040178523 Molded waveguides |
| 09/16/2004 | DE10350280A1 New complex comprising cucurbituril and fullerene coupled with each other by molecular interaction, useful as a medicine delivery means in the field of pharmaceutics |
| 09/16/2004 | DE10256558A1 Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe Esters of polysaccharide aldonic acids, process for their preparation and use for coupling to active pharmaceutical ingredients |
| 09/16/2004 | CA2547939A1 Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof |
| 09/16/2004 | CA2518237A1 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 09/16/2004 | CA2518148A1 Long acting injectable insulin composition and methods of making and using thereof |
| 09/16/2004 | CA2518143A1 Delivery system for drug and cell therapy |
| 09/16/2004 | CA2518136A1 Oral insulin composition and methods of making and using thereof |
| 09/16/2004 | CA2518119A1 Trans-membrane-antibody induced inhibition of apoptosis |
| 09/16/2004 | CA2517939A1 Peptides that specifically bind hgf receptor (cmet) and uses thereof |
| 09/16/2004 | CA2517158A1 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer |
| 09/16/2004 | CA2517145A1 Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 09/16/2004 | CA2516677A1 Intracellular delivery of small molecules proteins and nucleic acids |